uploads///Bydureon

The Performance of AstraZeneca’s Bydureon and Byetta in 2017

By

Mar. 5 2018, Updated 7:31 a.m. ET

Bydureon’s revenue trends

In 4Q17, AstraZeneca’s (AZN) Bydureon reported revenues of $147.0 million, which reflected ~4.0% growth on a year-over-year (or YoY) basis and ~15.0% growth on a quarter-over-quarter basis.

In fiscal 2017, Bydureon generated revenues of $574.0 million, which reflected an ~1.0% YoY decline.

 

In 2017 in the US market, Bydureon reported revenues of $458.0 million, which reflected an ~1.0% YoY decline. Increasing market competition and pricing pressures primarily contributed to the slight decline in revenues in the United States.

In 3Q17 in the US market, AstraZeneca launched Bydureon BCise, an injectable suspension autoinjector, which is a once-weekly, single-dose autoinjector device. The new product launch is expected to boost Bydureon’s revenue growth in 2018.

In Europe and emerging markets in 2017, Bydureon reported revenues of $88.0 million and $9.0 million, respectively. In Europe in 2017, Bydureon witnessed a 12.0% decline on a YoY basis. Rising market competition primarily led to the decline of Bydureon’s revenues.

In 2016, AstraZeneca entered into a collaboration with 3SBio, granting 3SBio commercialization rights of Bydureon in China.

Article continues below advertisement

Byetta’s revenue trends

In 4Q17, Byetta reported revenues of $48.0 million, which reflected an ~13.0% YoY decline and 23.0% growth on a quarter-over-quarter basis. 

In the diabetic care market, AstraZeneca’s Bydureon and Byetta compete with Novo Nordisk’s (NVO) Victoza and Ozempic, GlaxoSmithKline’s (GSK) Tanzeum, and Eli Lilly’s (LLY) Trulicity.

Symlin’s revenue trends

In 4Q17, Symlin reported revenues of $13.0 million, which reflected ~30.0% growth on a quarter-over-quarter basis. In fiscal 2017, Symlin generated revenues of $48.0 million, which is ~20.0% YoY growth.

Advertisement

More From Market Realist

  • SemiLEDS logo over LED lighting
    Company & Industry Overviews
    There's Still Time to Get in on SemiLEDS (LEDS) Stock
  • Trader on the NYSE
    Company & Industry Overviews
    What Are the Most Expensive Stocks Ever?
  • Michelob Ultra beer
    Company & Industry Overviews
    AB InBev Is the Top Beer Brand Worldwide—Is It a Monopoly?
  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.